News Release

Research Article Cites HemoVoid™ in Biomarker Study for Obstructive Sleep Apnea

MONMOUTH JUNCTION, NJ, December 3, 2020 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology to observe and report the red blood cell (RBC) proteome by two dimensional difference gel electrophoresis (2D-DIGE) in Obstructive Sleep Apnea (OSA).

The citation is:

Valentim-Coelho, Cristina, et al. "Redox–Oligomeric State of Peroxiredoxin-2 and Glyceraldehyde-3-Phosphate Dehydrogenase in Obstructive Sleep Apnea Red Blood Cells under Positive Airway Pressure Therapy." Antioxidants 9.12 (2020): 1184.

In this study, the authors examined the effect of six months of positive airway pressure (PAP) therapy on patients with Obstructive Sleep Apnea (OSA). The red blood cell (RBC) proteome was analyzed by two dimensional difference gel electrophoresis (2D-DIGE) - based proteomics followed by Western blotting (WB) validation. In the Discovery Phase, for 2D-DIGE Proteomics, the article states “RBC samples (Cohort I) were lysed by incubation with 5 mM phosphate buffer pH 7.4 (1:20) containing 1:100 cocktail of protease inhibitors … for 30 min at 4◦C followed sonication…. After centrifugation …, the supernatants were recovered for further hemoglobin (Hb) depletion using HemoVoid™ depletion columns (Biotech Support Group, Monmouth JCT, NJ, USA), according to the manufacture’s protocol.” The results indicated that the redox–oligomeric state of GAPDH and PRDX2 involving overoxidation by sulfinic/sulfonic acids were differentially modulated in OSA RBC, which might be compromising RBC homeostasis. Therefore, information on the redox status of PRDX2 and GAPDH in RBC will help to better recognize OSA subtypes and predict the therapeutic response to positive airway pressure (PAP) therapy in these patients. 

“We have focused our development efforts around proteomic profiling of the various blood compartments. I am very pleased to see another article illustrating the ability to enrich for the underlying sub-proteome from the cytosolic fraction of red cells as a unique feature of HemoVoid™. That two differentially expressed proteins were identified in this study, demonstrates its flexibility for a wide variety of applications”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information oo all of BSG’s Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to  http://www.biotechsupportgroup.com.

For Business Development, contact:

Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com